Insulin, Aspart, Human Cartridge

Brand(s)
NovoLog
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Novo Nordisk (2015-04-17)
Oldest Current Product
2001-08-27
License(s)
NDA
RxNORM
CARTRIDGE\INSULIN, ASPART, HUMAN
FDAOB
SUBCUTANEOUS\INJECTION\INSULIN ASPART RECOMBINANT
SPL Active
INTRAVENOUS\INJECTION, SOLUTION\INSULIN ASPART
SPL Moiety
INTRAVENOUS\INJECTION, SOLUTION\INSULIN ASPART

product(s) by strength(s)

3 ml insulin, aspart, human 100 unt/ml cartridge

original product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1001693303NovoLogNDANovo Nordisk2001-08-27INSULIN ASPARTINTRAVENOUSINJECTION, SOLUTIONNDA0209863a1e73a2-3009-40d0-876c-b4cb2be56fc5

application(s)

#idtitleapplicantapprovedpatentapproved drugin other drug docs
1NDA020986NOVOLOGNOVO NORDISK INC2000-06-07p9132239, SUBSTANCE
p7686786, SUBSTANCE
p8684969, SUBSTANCE
p5866538, SUBSTANCE
p5693027, SUBSTANCE
p8672898, SUBSTANCE
p6899699, SUBSTANCE
p8920383, SUBSTANCE
p6004297, SUBSTANCE
pRE43834, SUBSTANCE
pRE41956, SUBSTANCE
p9108002, SUBSTANCE
NDA020986_001, NDA020986_002, NDA020986_003, NDA020986_004, NDA020986_005Insulin, Aspart, Human Pen Injector
Insulin, Aspart, Human Injectable Solution

application drug(s)

#idcategory/deprecatedingredient strength(s)routedose formrldapprovedapplication
1NDA020986_001RXINSULIN ASPART RECOMBINANT (1000 UNITS/10ML)SUBCUTANEOUSINJECTIONTrue2000-06-07NOVOLOG
2NDA020986_002RXINSULIN ASPART RECOMBINANT (300 UNITS/3ML)SUBCUTANEOUSINJECTIONTrue2000-06-07NOVOLOG
3NDA020986_003RXINSULIN ASPART RECOMBINANT (300 UNITS/3ML)SUBCUTANEOUSINJECTIONTrue2001-01-19NOVOLOG
4NDA020986_004discontinuedINSULIN ASPART RECOMBINANT (300 UNITS/3ML)SUBCUTANEOUSINJECTIONFalse2004-04-23NOVOLOG
5NDA020986_005RXINSULIN ASPART RECOMBINANT (300 UNITS/3ML)SUBCUTANEOUSINJECTIONTrue2013-10-31NOVOLOG

patent(s)

#idexpiration dateapplication(s)in other drug docs
1p5693027 (view patent)2014-12-02NDA020986Insulin, Aspart, Human Pen Injector
Insulin, Aspart, Human Injectable Solution
2p5866538 (view patent)2017-06-20NDA020986, NDA021172, NDA021536, NDA021810, NDA203313insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart Protamine, Human / Insulin, Aspart, Human Pen Injector
Insulin, Aspart, Human Injectable Solution
Insulin, Aspart Protamine, Human / Insulin, Aspart, Human Injectable Suspension
3p6004297 (view patent)2019-01-28NDA020986, NDA021148, NDA021172, NDA021536, NDA022341insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart Protamine, Human / Insulin, Aspart, Human Pen Injector
Insulin, Aspart, Human Injectable Solution
Insulin, Aspart Protamine, Human / Insulin, Aspart, Human Injectable Suspension
4p6899699 (view patent)2022-01-02NDA020986, NDA021148, NDA021536, NDA203313, NDA203314, NDA206321insulin degludec Pen Injector
insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart, Human Injectable Solution
5p7686786 (view patent)2026-08-03NDA020986, NDA021148, NDA021536, NDA203313, NDA203314, NDA206321insulin degludec Pen Injector
insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart, Human Injectable Solution
6p8672898 (view patent)2022-01-02NDA020986, NDA021148, NDA021536, NDA203313, NDA203314, NDA206321insulin degludec Pen Injector
insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart, Human Injectable Solution
7p8684969 (view patent)2025-10-20NDA020986, NDA021148, NDA021536, NDA203313, NDA203314, NDA206321insulin degludec Pen Injector
insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart, Human Injectable Solution
8p8920383 (view patent)2026-07-17NDA020986, NDA021148, NDA021536, NDA203313, NDA203314, NDA206321insulin degludec Pen Injector
insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart, Human Injectable Solution
9p9108002 (view patent)2026-01-20NDA020986, NDA021148, NDA021536, NDA203313, NDA203314, NDA206321insulin degludec Pen Injector
insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart, Human Injectable Solution
10p9132239 (view patent)2032-02-01NDA020986, NDA021148, NDA021536, NDA203313, NDA203314, NDA206321insulin degludec Pen Injector
insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart, Human Injectable Solution
11pRE41956 (view patent)2021-01-21NDA020986, NDA021148, NDA021172, NDA021536, NDA022341insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart Protamine, Human / Insulin, Aspart, Human Pen Injector
Insulin, Aspart, Human Injectable Solution
Insulin, Aspart Protamine, Human / Insulin, Aspart, Human Injectable Suspension
12pRE43834 (view patent)2019-01-28NDA020986, NDA021148, NDA021172, NDA021536, NDA022341insulin detemir Pen Injector
Insulin, Aspart, Human Pen Injector
Somatropin Injectable Solution
Somatropin Prefilled Syringe
liraglutide Pen Injector
insulin detemir Injectable Solution
Insulin, Aspart Protamine, Human / Insulin, Aspart, Human Pen Injector
Insulin, Aspart, Human Injectable Solution
Insulin, Aspart Protamine, Human / Insulin, Aspart, Human Injectable Suspension

spl(s)

#idtitlecategorytypelabelerlabeler actlast updateversionproduct(s)in other drug docs
13a1e73a2-3009-40d0-876c-b4cb2be56fc5 (view SPL)These highlights do not include all the information needed to use NovoLog safely and effectively. See full prescribing information for NovoLog.NovoLog (insulin aspart [rDNA origin] injection) solution for subcutaneous useInitial U.S. Approval: 2000prescriptionHuman PrescriptionNovo NordiskMANUFACTURE2015-04-1719001693303, 001696338, 001696339, 001697501Insulin, Aspart, Human Pen Injector
Insulin, Aspart, Human Injectable Solution

Data from: FDAOB, FDAPB, LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII